WCN25-661 Switching Strategies: Evaluating the Safety and Efficacy of Non-Steroidal Mineralocorticoid Antagonists (ns MRA) in Spironolactone- non tolerant Post-Transplant Recipients

Mineralocorticoid receptor antagonists (MRAs) are a cornerstone of chronic heart and kidney disease management. However, their use in post-renal transplant patients is limited due to side effects such as hyperkalemia, gynecomastia, and a decline in estimated glomerular filtration rate (eGFR). This retrospective study aimed to assess the safety and efficacy of finerenone, a new non-steroidal MRA (nsMRA), in post-renal transplant patients in whom spironolactone (Sp) were discontinued or not started due to side effects or hyperkalaemia.